Why Is BrainChip (ASX:BRN) Trading on Unusually High Volume Today?

Sonal Goyal

26 October 2026 09:32 PM AEDT

Why Is BrainChip (ASX:BRN) Trading on Unusually High Volume Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

BrainChip (ASX:BRN) traded at $0.11, down 4.35%, on Volume of 5,006,977 shares during the 26 October 2026 session.
Sequora processor IP completed development and is available for commercial licensing from 14 October 2026.
The company said it cannot yet give reliable forecasts of licensing revenue, adoption or financial impact.

BrainChip Holdings Ltd (ASX:BRN) traded at $0.11, down 4.35%, on volume of 5,006,977 shares during the Trading session on 26 October 2026. The volume was unusual, meaning at least 50% above the stock's Average Daily Volume over the last month. BrainChip is a Sydney-based company, also quoted on the OTCQX, that develops ultra-low power, event-based neuromorphic AI processors. Its latest product announcement is dated 14 October 2026.

Sequora Released on 14 October 2026

BrainChip announced that the Sequora processor intellectual property core has completed development and is available for commercial licensing to semiconductor and system developers. The company said it is delivered to the timeline outlined in its May 2026 roadmap presentation.

Sequora is designed for generative AI workloads at the edge, where power efficiency, memory use and local processing matter. It is offered as IP that customers incorporate into their own system-on-chip designs, together with software and development tools.

Capabilities Described by the Company

BrainChip states that Sequora keeps the advantages of its existing Akida technology, including ultra-low power operation and independence from a cloud connection, which it links to data sovereignty, speed and lower cloud costs. It adds generative AI and large language model capability on the device, supports model sizes up to about 3 billion parameters, and enhances run-time branching to support automotive, medical and avionics certification.

Potential application areas named are industrial, automotive, aerospace and defence, consumer and medical markets.

What the Company Says About Financial Impact

The announcement says it marks a key milestone in commercialisation and that customer engagement has begun. BrainChip stated that it is not currently in a position to provide reliable forecasts of future licensing revenue, customer adoption rates or financial impact, and that any material customer contracts or developments will be disclosed under its continuous disclosure obligations.

Edge AI refers to running artificial intelligence on the device itself rather than in a remote data centre. BrainChip's release links this approach to benefits in battery life, data sovereignty, latency and cloud cost. Run-time branching, which the company says Sequora enhances, is a feature that supports the certification requirements of automotive, medical and avionics systems.

About BrainChip

BrainChip describes Akida as a fully digital, event-based AI processor that uses neuromorphic principles to analyse essential sensor inputs at the point of acquisition. Its Temporal Event-based Neural Networks build on state-space models for real-time streaming applications across aerospace, autonomous vehicles, robotics, industrial IoT, consumer devices and wearables.

BrainChip's quoted listings include the ASX under BRN, the OTCQX under BRCHF and an American depositary receipt programme under BCHPY. The announcement was authorised for release by the board, and contact details were provided for Investor relations and a media adviser. The company has positioned Sequora as an addition to its product portfolio alongside Akida, expanding the range of applications from sensor processing towards on-device generative AI.

Risks

The company has not forecast licensing Revenue and says adoption is not yet predictable. Sequora is licensed IP, so revenue depends on customers adopting it in their own chip designs. The release contains no customer contracts or revenue figures.

Catalysts on Investors' Radar

Any announcement of licensing agreements, customer developments or further roadmap milestones would be released under the company's continuous disclosure obligations.

Final Perspective

BrainChip traded on unusually high volume with a lower price on 26 October, twelve days after announcing Sequora's availability. The announcement is a product milestone without financial figures.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.